• Citer

Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.

par Awada, Ahmad ;Dirix, L.;Manso Sanchez, L;Xu, B;Luu, T;Diéras, Véronique;Hershman, D L;Agrapart, V;Ananthakrishnan, R;Staroslawska, E
Référence Annals of oncology, 24, 1, page (109-116)
Publication Publié, 2013-01

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.
Auteur:	Awada, Ahmad; Dirix, L.; Manso Sanchez, L; Xu, B; Luu, T; Diéras, Véronique; Hershman, D L; Agrapart, V; Ananthakrishnan, R; Staroslawska, E
Informations sur la publication:	Annals of oncology, 24, 1, page (109-116)
Statut de publication:	Publié, 2013-01
Sujet CREF:	Cancérologie
Mots-clés:	Breast cancer
	HER2
	Neratinib
	Tyrosine kinase inhibitor
	Vinorelbine
MeSH keywords:	Adult
	Antineoplastic Combined Chemotherapy Protocols -- administration & dosage -- adverse effects -- therapeutic use
	Breast Neoplasms -- drug therapy -- metabolism -- pathology
	Female
	Humans
	Male
	Middle Aged
	Neoplasm Metastasis
	Quinolines -- administration & dosage -- adverse effects -- therapeutic use
	Receptor, ErbB-2 -- metabolism
	Vinblastine -- administration & dosage -- adverse effects -- analogs & derivatives -- therapeutic use
Note générale:	Journal Article
	Research Support, Non-U.S. Gov't
	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0923-7534
	info:doi/10.1093/annonc/mds284
	info:pii/mds284
	info:scp/84871595073
	info:pmid/22967996